Centauri Therapeutics
To add a bio or update company history, please click update information.
News from Centauri Therapeutics
Centauri Therapeutics
24 Feb 2026
Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy
Centauri Therapeutics is a biotechnology startup developing immunotherapies using its Alphamer platform. Its treatments are designed to harness the body’s immune response to target infectious diseases, including multidrug-resistant bacteria.
Centauri Therapeutics
29 Jul 2025
Centauri Therapeutics secures a further £3.8m from CARB-X to advance antimicrobial candidate into clinical trials
Centauri Therapeutics develops antimicrobial therapies based on a proprietary immunotherapy platform, with its lead candidate designed to treat serious drug resistant bacterial infections of the lung.
Centauri Therapeutics
- Life Sciences
- Cheshire, United Kingdom
- £9.8m
- centauritherapeutics.com
- Update Information
More venture news
- 23 Jun 2026
TRIMTECH TherapeuticsTRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
ExtensionLife Sciences - 19 Jun 2026
Houdini BioHoudini Bio launches with a £1.5m pre-seed led by SCVC to tackle gene silencing with machine learning DNA design platform
Pre-seedLife Sciences - 3 Jun 2026
ApohaApoha unlocks £27m in funding led by Singular to measure how molecules and materials behave under real-world conditions
EquityLife Sciences
